Junshida (ongericimab) / Shanghai Junshi Biosci, Chongqing Bochuang Pharmaceuticals - LARVOL DELTA

JS002 - Late-breaking research from CMI & CMI Comms - on invasive infections and antimicrobial resistance (ESCMID Global 2026) - No abstract available

Late-breaking abstract • Infectious Disease

EFFICACY AND SAFETY OF ONGERICIMAB IN PATIENTS WITH DYSLIPIDEMIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (ACC 2026) - "Ongericimab is a potent lipid-lowering agent with a favorable short-term safety profile, offering potential for patients requiring intensive LDL-C reduction."

Retrospective data • Review • Dyslipidemia • Metabolic Disorders • APOA1

Efficacy and safety of Ongericimab in patients with dyslipidemia: a systematic review and meta-analysis (HEART FAILURE 2026) - No abstract available

Retrospective data • Review • Cardiovascular • Dyslipidemia

Efficacy and safety of ongericimab in patients with dyslipidemia: A GRADE-assessed systematic review and meta-analysis of randomized controlled trials. (PubMed, J Clin Lipidol) - "Ongericimab is a potent lipid-lowering agent with a favorable short-term safety profile, offering potential for patients requiring intensive LDL-C reduction. While findings are consistent and clinically compelling, they are derived solely from short-duration trials in Chinese populations and are limited to surrogate endpoints. Large, multiethnic cardiovascular outcomes trials are essential to confirm long-term benefits, assess rare adverse events, and establish its position among global lipid-lowering strategies."

Journal • Retrospective data • Review • Cardiovascular • Dermatology • Dyslipidemia • Infectious Disease • Metabolic Disorders • Nephrology • Respiratory Diseases • APOA1

The Efficacy and Safety of Four Novel PCSK9 Monoclonal Antibodies in Patients With Hypercholesterolemia: A Systematic Review With Network Meta-Analysis and Trial Sequential Analysis. (PubMed, Cardiovasc Ther) - "These findings positioned ongericimab 150 mg Q2W as a clinically optimal PCSK9 inhibitor with robust lipid-lowering capacity. The results highlight the potential of next-generation PCSK9 monoclonal antibodies, particularly in East Asian populations, while underscoring the need for large-scale multinational trials to validate ethnic-specific responses."

Biomarker • Clinical • Journal • Retrospective data • Review • Dyslipidemia • Metabolic Disorders • APOB

Efficacy and safety of proprotein convertase subtilisin/kexin type 9 inhibitors for adults with familial hypercholesterolemia: A network meta-analysis. (PubMed, Int J Cardiol Cardiovasc Risk Prev) - "In heterozygous FH (HeFH) populations, ongericimab showed the greatest reductions in LDL-C (mean difference [MD]: -74.98 %), ApoB (MD: -64.64 %), and Lp(a) (MD: -59.66 %), with SUCRA rankings of 68.7 %, 63.6 %, and 95.0 %, respectively...In terms of safety, lerodalcibep showed the most favorable profile for injection-site reactions and ALT >3 × ULN, with SUCRA values of 98.5 % and 96.7 %, respectively...Inclisiran's efficacy may be underestimated due to short-term follow-up. Monotherapy with PCSK9 inhibitors has limited efficacy in HoFH patients, highlighting the need for combination therapies."

Clinical • Journal • Retrospective data • Review • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Heterozygous Familial Hypercholesterolemia • Homozygous Familial Hypercholesterolemia • Metabolic Disorders • APOB

ORIS: Ongericimab Injection Reducing Recurrence of Ischemic Stroke (clinicaltrials.gov) - P3 | N=4398 | Not yet recruiting | Sponsor: Beijing Tiantan Hospital

New P3 trial • Atherosclerosis • Cardiovascular • CNS Disorders • Ischemic stroke

Comparative Efficacy of Ongericimab Versus Six PCSK9 Inhibitors in Treating Hypercholesterolemia or Mixed Dyslipidemia: A Network Meta-Analysis (ISPOR-EU 2025) - "This study aimed to assess the relative lipid-lowering efficacy of ongericimab compared with other PCSK9 inhibitors through a network meta-analysis (NMA). We conducted a systematic literature review (SLR) to identify phase 3 randomized controlled trials (RCTs) of ongericimab and six other PCSK9 inhibitors (evolocumab, alirocumab, tafolecimab, recaticimab, ebronucimab, and inclisiran) assessing efficacy in adult patients with hypercholesterolemia or mixed dyslipidemia, compared with background lipid-lowering therapies. Ongericimab demonstrated superior efficacy in reducing LDL-C and Lp(a) levels compared with most existing PCSK9 inhibitors. These findings may inform clinical decisions and support formulary positioning in lipid-lowering treatment strategies."

Retrospective data • Dyslipidemia • Metabolic Disorders • Mixed Hyperlipidemia

ONTOP: Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial (clinicaltrials.gov) - P2 | N=32 | Not yet recruiting | Sponsor: Shanghai Pudong Hospital

New P2 trial • pMMR • Colorectal Cancer • Oncology • Solid Tumor

Efficacy and safety of different proprotein convertase subtilisin/kexin type 9 inhibitors in the general population and solid organ transplant recipients: a network meta-analysis. (PubMed, Front Pharmacol) - "Inclisiran increased risks of total AEs and injection site reactions (RR > 1.2). Evolocumab is optimal for LDL-C and CVE reduction, while Ongericimab and Alirocumab offer better safety profiles. PCSK9 inhibitors did not increase acute rejection or infection risk in SOT recipients. Long-term mortality benefits remain uncertain."

Journal • Retrospective data • Cardiovascular • Dyslipidemia • Infectious Disease • Solid Organ Transplantation • Transplant Rejection • Transplantation

Efficacy and safety of ongericimab in Chinese statin-intolerant patients with primary hypercholesterolemia or mixed dyslipidemia: a randomized, placebo-controlled phase 3 trial. (PubMed, Atherosclerosis) - P3 | "Ongericimab significantly reduced LDL-C as well as other atherogenic lipid levels and was well tolerated in Chinese statin-intolerant patients with primary hypercholesterolemia or mixed dyslipidemia."

Journal • P3 data • Dyslipidemia • Metabolic Disorders • Mixed Hyperlipidemia • APOB

Junshi Biosciences Announces Ongericimab’s sNDA Approval in China (GlobeNewswire) - "Shanghai Junshi Biosciences...announced that the National Medical Products Administration (the “NMPA”) has approved two supplemental new drug applications for the ongericimab injection (a recombinant humanized anti-PCSK9 monoclonal antibody injection, trade name: JUNSHIDA...for: 1) adult patients with heterozygous familial hypercholesterolemia ('HeFH'); 2) alone or in combination with ezetimibe, in adult patients with non-familial hypercholesterolemia and mixed dyslipidemia who are statin-intolerant or statins contraindicated. Ongericimab has become China’s first domestic PCSK9-targeted drug approved for statin-intolerant patients....The approval of the two supplemental new drug applications are mainly based on two registered clinical trials—JS002-005 (NCT05325203) and JS002-007 (NCT05621070)."

China approval • Heterozygous Familial Hypercholesterolemia

Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: A randomized, double-blind, placebo-controlled phase 3 trial. (PubMed, Atherosclerosis) - P3 | "Ongericimab administered at either 150 mg Q2W or 450 mg Q4W for 24 weeks, significantly reduced LDL-C levels and was well-tolerated in Chinese patients with HeFH."

Clinical • Journal • P3 data • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Heterozygous Familial Hypercholesterolemia • Metabolic Disorders

Clinical pharmacokinetics and pharmacodynamics of ongericimab: A potential long-acting PCSK9 monoclonal antibody in healthy subjects and patients with hypercholesterolemia: Randomized, double-blind, placebo-controlled phase Ia and Ib/II studies. (PubMed, Clin Transl Sci) - "At the end of the dosing interval in the phase Ib/II study, over 70% of patients' LDL-C levels decreased by more than 50% from baseline. The results showed that ongericimab had a significant long-acting LDL-C lowering effect with good safety and potential for clinical application."

Clinical • Journal • P1 data • PK/PD data • Dyslipidemia • Metabolic Disorders

Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia (clinicaltrials.gov) - P3 | N=582 | Recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Not yet recruiting ➔ Recruiting | Trial primary completion date: Oct 2023 ➔ Sep 2024

Enrollment open • Monotherapy • Trial primary completion date • Dyslipidemia • Metabolic Disorders • Mixed Hyperlipidemia

A Pharmacokinetic Study of JS002 in Healthy Subjects (clinicaltrials.gov) - P1 | N=318 | Completed | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Active, not recruiting ➔ Completed | Trial completion date: Dec 2023 ➔ Sep 2023

Trial completion • Trial completion date

Efficacy and safety of ongericimab in Chinese statin intolerant patients with primary hypercholesterolemia or mixed dyslipidemia (ESC 2024) - No abstract available

Clinical • Cardiovascular • Dyslipidemia

To Evaluate the Efficacy and Safety of JS002 in HoFH Patients (clinicaltrials.gov) - P2 | N=31 | Completed | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Active, not recruiting ➔ Completed

Trial completion • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Homozygous Familial Hypercholesterolemia • Metabolic Disorders

Efficacy and safety of ongericimab given by prefilled syringe or autoinjector in primary hypercholesterolemia and mixed hyperlipidemia. (PubMed, Nutr Metab Cardiovasc Dis) - "In Chinese patients with primary hypercholesterolemia and mixed dyslipidemia, a 12-week treatment regimen with ongericimab administered by PFS or AI significantly reduced LDL-C and other lipid parameters, proving to be safe and well tolerated. Patients experienced consistent effects from PFS or AI devices."

Journal • Dyslipidemia • Metabolic Disorders

Efficacy and Safety of Ongericimab in Chinese Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia. (PubMed, J Am Heart Assoc) - P3 | "Ongericimab, as an add-on treatment to optimized lipid-lowering therapy, significantly reduced LDL-C and was well-tolerated in Chinese patients with primary hyperlipidemia and mixed dyslipidemia who did not achieve their LDL-C targets."

Journal • Dyslipidemia • Metabolic Disorders

A Study Explore JS001+JS002 in Patients With Advanced Cancer (clinicaltrials.gov) - P1 | N=9 | Terminated | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | N=114 ➔ 9 | Trial completion date: Apr 2024 ➔ Nov 2023 | Recruiting ➔ Terminated | Trial primary completion date: Feb 2024 ➔ Nov 2023; The regimen of JS002 75~300mg Q3W has been completed, and the combination therapy is well tolerated and safe. However, considering that the efficacy did not reach the preset, it is recommended to terminate the trial in advance.

Enrollment change • Metastases • Trial completion date • Trial primary completion date • Trial termination • Gastrointestinal Cancer • Lung Cancer • Oncology • MSI • PD-1 • PD-L1 • TMB

A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH). (clinicaltrials.gov) - P3 | N=135 | Completed | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Recruiting ➔ Completed

Trial completion • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Heterozygous Familial Hypercholesterolemia • Metabolic Disorders

Efficacy and Safety of Ongericimab in Chinese Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia (AHA 2023) - P3 | "Eligible patients receiving stable statin (±ezetimibe) therapy but not achieving LDL-C goals were enrolled. Ongericimab on stable background LLT significantly reduced LDL-C and was well tolerated in Chinese patients with primary hypercholesterolemia and mixed dyslipidemia."

Clinical • Dyslipidemia • Metabolic Disorders

A Pharmacokinetic Study of JS002 in Healthy Subjects (clinicaltrials.gov) - P1 | N=318 | Active, not recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Not yet recruiting ➔ Active, not recruiting

Enrollment closed

A Pharmacokinetic Study of JS002 in Healthy Subjects (clinicaltrials.gov) - P1 | N=318 | Not yet recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd.

New P1 trial